Posts Tagged: Ted Sargent
Xagenic announces $6 million GAAP partnership for Hepatitis C testing; appoints president and CEO
Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, announced October 15, 2014 that its project in partnership with the University of Toronto was successful in securing funding from Genome Canada under the Genomic Applications Partnership Program (GAPP).
The funding, announced by the Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, is part of 12 selected projects under Genome Canada’s Genomic Applications ...
Read more
U of T researchers demonstrate new class of solar-sensitive nanoparticle
New research emerging from the University of Toronto's Edward S Rogers Sr. Department of Electrical and Computer Engineering is developing and demonstrating a new class of solar-sensitive nanoparticle.
MaRS Innovation is working with Professor Ted Sargent, his research team and U of T's Innovations and Partnerships Office (IPO) to incubate and commercialize this and other solar technologies. Their work was recently published in Nature Materials.
The paper's publication was widely covered in the technical trades, including CNET.com, Tech Times, Compound Semiconductor.net and ...
Read more
Xagenic founder Shana Kelley’s MRI blog post on bringing research to market
U of T professor shares tips to her team's commercialization success
When it comes to bringing research from the lab to the market, the University of Toronto’s Dr. Shana Kelley knows firsthand what it takes. She’s co-founder of Xagenic, a MaRS Innovation and U of T start-up company that’s developed the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on her research with fellow U of T colleague Professor Edward Sargent.
Xagenic recently announced a Series B financing announcement following their successful $10 million ...
Read more
MaRS Innovation’s 2013 Top 10 List
2013 was an exceptional year for MaRS Innovation. Here are the top 10 news stories from our commercialization portfolio.
1. MaRS Innovation secures a $15 million CECR funding extension
In January, MaRS Innovation was one of four Centres of Excellence for Commercialization and Research to be successfully extended by the Networks of Centres of Excellence of Canada.
This achievement reflects and recognizes the quality of the startups and licensable technologies within the MaRS Innovation portfolio, as well as the rigour of its business model and the achievements of its ...
Read more
Dr. Hofstein’s Op-Ed for The Hill-Times, “Biotechnology research: A knowledge economy”
This op-ed on Canadian biotechnology and the knowledge economy appeared in The Hill-Times (subscription required), Canada's politics and government newsweekly, September 9:
Obesity, cancer, heart disease and stroke, diabetes, Parkinson’s disease, Alzheimer’s, or the more general stresses of an aging population: no matter which area of concern holds our collective gaze from moment to moment, improving health outcomes and healthcare is the No. 1 challenge for the world’s economy.
Canada has the holistic approach and translational research necessary to address health care’s pervasive ...
Read more
Xconomy names Xagenic to 2012’s Biotech Startup Class
MI spin-off company one of 30 listed in North America and the United Kingdom
Xconomy, a U.S.-based business news website, named Xagenic to its 2012 Biotech Startup Class.
Luke Timmerman's article, published December 3, 2012, sited Xagenic as one of only 30 "exciting biotech startups" to raise significant venture capital (at least $5 million) in the life sciences sector.
Xagenic, founded by Drs. Shana Kelley and Ted Sargent at the University of Toronto, was also the only Canadian company named to the list. (more…)
Read more
BioCentury Features Xagenic’s PCR-Based Infection-Diagnosis Technology
Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury.
Here's an excerpt (the article only available to BioCentury subscribers):
PCR-based diagnosis of infections can delay treatment decisions by days or hours because the method relies on technical expertise and equipment not available in most point-of-care settings. Xagenic Inc.'s chip-based arrays use a non-PCR, electrochemical approach to diagnose bacterial infections at the point of care in 20 minutes with PCR-like accuracy.
Xagenic's core technology is a silicon chip containing ...
Read more